Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
The U.S. Department of Defense Prostate Cancer Research Program has awarded the Data Science Award and a $1.2 million grant to researchers Charles Gaber, Natalie Reizine, Todd Lee, Lucia Petito, and Jessica Islam.
